Skip to main content

Advertisement

SpringerLink
Log in

High incidence of intolerance to tuberculosis chemoprophylaxis

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

The outlook of inflammatory joint diseases has changed significantly with the advent of TNF blockers. However, these advances come with a trade off—risk of infections, especially tuberculosis. The Irish society of rheumatology has proposed guidelines to investigate and treat latent TB infection (LTBI), which is in accordance with majority of international recommendations. This protocol requires that every patient with LTBI should have chemoprophylaxis. INH and different anti-rheumatic drugs are known to cause hepatic and gastrointestinal complications. We sought to investigate the toxicity of adding prophylactic anti-TB medications to different DMARDs and anti-TNF agents. We prospectively documented the course of all patients who were prescribed chemoprophylaxis for LTBI, from August 2007 to August 2008. Arrangements were made for central re-issuing of prescription of INH or rifampicin, after reviewing monthly liver function tests and following telephone interview seeking presence of adverse events. Out of 132 patients who were commenced on different TNF blockers, only 23 patients (17%) were diagnosed with LTBI and were given prophylaxis as per recommended guidelines. Thirty-nine percent (9 out of 23) of patients discontinued INH because of adverse events. Primary reason for discontinuation in these 9 patients was as follows: 3 patients got marked transaminitis (transaminases >5 times the normal limit), 5 patients had non-resolving gastrointestinal intolerance (mainly nausea), and one patient developed non-resolving rash. We have found a significant number of our patients (39%) who could not continue anti-TB prophylaxis due to either gastrointestinal intolerance or hypertransaminesemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. http://www.isr.ie/_fileupload/File/ISR%20Guidelines%20A4%20(3).pdf

  2. British Thoracic Society, Standards of Care Committee (2005) BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-{alpha} treatment. Thorax 60:800–805

    Article  Google Scholar 

  3. Lee WM (1995) Drug-induced hepatotoxicity. N Engl J Med 333:1118–1127

    Article  PubMed  CAS  Google Scholar 

  4. Mitchell JR, Zimmerman HJ, Ishak KG et al (1976) Isoniazid liver injury: clinical spectrum, pathology and probable pathogenesis. Ann Intern Med 84:181–192

    PubMed  CAS  Google Scholar 

  5. Mor A, Bingham CO 3rd, Kishimoto M, Izmirly PM, Greenberg JD, Reddy S, Rosenthal PB (2008) Methotrexate combined with isoniazid treatment for latent tuberculosis is well tolerated in patients with rheumatoid arthritis: experience from an urban arthritis clinic. Ann Rheum Dis 67(4):462–465

    Article  PubMed  CAS  Google Scholar 

  6. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G et al (1999) Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 159:2542–2550

    Article  PubMed  CAS  Google Scholar 

  7. Leak AM, Rincon-Aznar B (2008) Hepatotoxicity associated with etanercept in psoriatic arthritis. J Rheumatol 35(11):2286–2287

    Article  PubMed  Google Scholar 

  8. Garcia Aparicio AM, Rey JR, Sanz AH, Alvarez JS (2007) Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab. Clin Rheumatol 26(5):811–813

    Article  PubMed  Google Scholar 

  9. Brassard P, Lowe AM, Bernatsky S, Kezouh A, Suissa S (2009) Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum 61(3):300–304

    Article  PubMed  Google Scholar 

  10. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR et al (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59:762–784

    Article  PubMed  CAS  Google Scholar 

  11. Centers for Disease Control and Prevention (2004) Tuberculosis associated with blocking agents against tumor necrosis factor-alpha—California, 2002–2003. MMWR Morb Mortal Wkly Rep 53:683–686

    Google Scholar 

  12. Keane J, Bresnihan B (2008) Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies. Curr Opin Rheumatol 20(4):443–449

    Article  PubMed  CAS  Google Scholar 

  13. Raval A, Akhavan-Toyserkani G, Brinker A et al (2007) Brief communication: characteristics of spontaneous cases of tuberculosis associated with infliximab. Ann Intern Med 147:699–702

    PubMed  Google Scholar 

  14. Gómez-Reino JJ, Carmona L, Angel Descalzo M, Biobadaser Group (2007) Risk of tuberculosis in patients treated with tumour necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 57(5):756–761

    Article  PubMed  Google Scholar 

  15. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V et al (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52:1766–1772

    Article  PubMed  CAS  Google Scholar 

  16. Sezer I, Kocabas H, Melikoglu MA, Arman M (2009) Positiveness of purified protein derivatives in rheumatoid arthritis patients who are not receiving immunosuppressive therapy. Clin Rheumatol 28(1):53–57

    Article  PubMed  Google Scholar 

  17. Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D (2006) Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 10(10):1127–1132

    PubMed  CAS  Google Scholar 

  18. Vanhoof J, Landewe S, Van Wijngaerden E, Geusens P (2003) High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors. Ann Rheum Dis 62(12):1241–1242

    Article  PubMed  CAS  Google Scholar 

  19. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM (2000) Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev (2):CD001363

  20. Hong Kong Chest Service, Tuberculosis Research Centre Madras, British Medical Research Council (1992) A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 145:36–41

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, Waterford Regional Hospital, Waterford, Ireland

    Muhammad Haroon, Una Martin & Joe Devlin

Authors
  1. Muhammad Haroon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Una Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joe Devlin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Muhammad Haroon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haroon, M., Martin, U. & Devlin, J. High incidence of intolerance to tuberculosis chemoprophylaxis. Rheumatol Int 32, 33–37 (2012). https://doi.org/10.1007/s00296-010-1571-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-010-1571-6

Keywords

Search

Navigation